• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-1/A filed by HCW Biologics Inc.

    6/18/26 1:05:14 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCWB alert in real time by email
    S-1/A 1 forms-1a.htm S-1/A

     

    As filed with the Securities and Exchange Commission on June 18, 2026

     

    Registration No. 333-296577

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    Amendment No. 1

    to

    FORM S-1

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    HCW BIOLOGICS INC.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   2834   82-5024477
    (State or Other Jurisdiction of   Primary Standard Industrial   (I.R.S. Employer
    Incorporation or Organization)   Classification Code Number   Identification Number)

     

    2929 N Commerce Parkway

    Miramar, FL 33025

    (954) 842-2024

    Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices

     

    Hing C. Wong, Ph.D.

    Chief Executive Officer

    HCW Biologics Inc.

    2929 N Commerce Parkway

    Miramar, FL 33025

    (954) 842-2024

    Name, Address Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service

     

    With a copy to:

     

    James Groth

    Clark Hill PLC

    130 E. Randolph St., Ste. 3900

    Chicago, IL 60601

    (312) 985-5900

     

    Yevgeniya (Jeny) Zarmon

    Clark Hill PLC

    210 Carnegie Center, Suite 102

    Princeton, NJ 08540

    (609) 785-2918

     

    Approximate Date of Commencement of Proposed Sale to the Public: From time to time after the effective date of this registration statement, as determined by market conditions.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a) of the Securities Act, may determine.

     

     

     

     
     

     

    EXPLANATORY NOTE

     

    HCW Biologics Inc. is filing this Amendment No. 1 to its Registration Statement on Form S-1 (File No. 333-296577) as an exhibits-only filing. Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16(a) of Part II of the Registration Statement, the signature page to the Registration Statement and the filed exhibits. The remainder of the Registration Statement is unchanged and has therefore been omitted.

     

     
     

     

    PART II

     

    Item 16. Exhibits.

     

    EXHIBIT INDEX

     

            Incorporated by reference

      Filed or
    Exhibit No.   Exhibit title   Form   File No.   Exhibit No.   Filing date  

    furnished herewith

    3.1   Amended and Restated Certificate of Incorporation   8-K   001-40591   3.1   07/26/2021    
    3.1a   Certificate of Amendment of Certificate of Incorporation, filed March 31, 2025   8-K   001-40591   3.1a   04/01/2025    
    3.1b   Certificate of Correction of the Certificate of Amendment of Certificate of Incorporation, filed April 1, 2025   8-K   001-40591   3.1b   04/01/2025    
    3.2   Amended and Restated Bylaws   8-K   001-40591   3.2   07/26/2021    
    4.1   Specimen Stock Certificate   S-1/A   333-256510   4.1   07/09/2021    
    4.2   Description of Securities   10-K   001-40591   4.2   03/29/2022    
    4.3   Form of New Warrant   8-K   001-40591   4.1   11/20/2025    
    4.4   Form of Common Stock Purchase Warrant   8-K   001-40591   4.1   02/19/2026    
    4.5   Form of Pre-Funded Common Stock Purchase Warrant   8-K   001-40591   4.2   02/19/2026    
    4.6   Form of Common Stock Warrant, dated May 7, 2025, between Company and Holder   10-Q   001-40591   10.13   08/18/2025    
    4.7   Form of Pre-Funded Common Stock Purchase Warrant   8-K   001-40591    4.1   5/21/2026    
    4.8  

    Form of Common Stock Purchase Warrant

      8-K   001-40591    4.2   5/21/2026    
    5.1   Opinion of Clark Hill PLC                  

    X

    10.1   Form of Inducement Agreement between the Company and Armistice Capital Management LLC   8-K   001-40591   10.1   11/20/2025    
    10.2   Securities Purchase Agreement, dated February 17, 2026, between Company and Purchaser   8-K   001-40591   10.2   02/19/2026    
    10.3   Amendment to Existing Warrants Agreement, dated February 17, 2026, between the Company and Purchaser   8-K   001-40591   10.3   02/19/2026    
    10.4   Form of Lock-up Agreement   S-1   333-393396   10.42   02/11/2026    
    10.5   Form of Indemnification Agreement between HCW Biologics Inc. and each of its officers and directors.   S-1/A   333-256510   10.1   07/09/2021    
    10.6+   2019 Equity Incentive Plan, as amended, and forms of agreement thereunder.   S-1/A   333-256510   10.2   07/09/2021    
    10.7+   First Amendment to 2019 Equity Incentive Plan.   S-1/A   333-256510   10.3   07/09/2021    
    10.8+   2021 Equity Incentive Plan and forms of agreement thereunder   S-1/A   333-256510   10.4   07/09/2021    
    10.9+   Employment Agreement, dated July 6, 2021, between Peter Rhode and HCW Biologics Inc.   S-1/A   333-256510   10.6   07/09/2021    
    10.10+   Employment Agreement, dated October 9, 2019, between Rebecca Byam and HCW Biologics Inc.   S-1/A   333-256510   10.7   07/09/2021    

     

    II-1
     

     

           

    Incorporated by reference

     

    Filed or

    furnished

    herewith

    Exhibit No.   Exhibit title   Form   File No.   Exhibit No.   Filing date  
    10.11+   Non-Employee Director Compensation Policy.   S-1/A   333-256510   10.8   07/09/2021    
    10.12+   Employment Agreement, dated June 18, 2021, between Dr. Hing C. Wong and HCW Biologics Inc.   S-1/A   333-256510   10.13   07/09/2021    
    10.13+   Executive Incentive Bonus Plan   S-1/A   333-256510   10.11   07/09/2021    
    10.14†   Exclusive License Agreement, dated December 24, 2020, between HCW Biologics Inc. and Wugen, Inc.   S-1/A   333-256510   10.10   07/09/2021    
    10.15†   Master Services Agreement, dated March 14, 2019, between HCW Biologics Inc. and EirGenix, Inc.   S-1/A   333-256510   10.12   07/09/2021    
    10.16†#   Purchase and Sale Agreement, by and between HCW Biologics Inc. and Wai 3300 Corporate Way, LLC, dated May 27, 2022   10-Q   001-40591   10.1   08/12/2022    
    10.17#   Loan Agreement by and between HCW Biologics Inc. and Cogent Bank, dated August 15, 2022   10-Q   001-40591   10.1   11/07/2022    
    10.18#   Mortgage and Security Agreement by and between HCW Biologics Inc. and Cogent Bank, dated August 15, 2022   10-Q   001-40591   10.2   11/07/2022    
    10.19   Form of Subscription Agreement, dated February 20, 2024, by and between the Company and the Subscribers party thereto   8-K   001-40591   10.1   02/22/2024    
    10.20   Form of Amended and Restated Senior Secured Note Purchase Agreement, dated July 2, 2024, by and between the Company and the Purchase party thereto   10-Q   001-40591   10.1   08/14/2024    
    10.21   Form of Amended and Restated Pledge Agreement, dated July 2, 2024, by and among the Company, Escrow Agent and Noteholder parties thereto   10-Q   001-40591   10.3   08/14/2024    
    10.22   Form of Escrow Agreement, dated May 1, 2025, by and between the Company, Escrow Agent and Noteholder party thereto   10-Q   001-40591   10.4   08/14/2024    
    10.23   Form of First Amendment to Amended and Restated Secured Note Purchase Agreement, dated September 30, 2024, by and between the Company and Purchaser party thereto   10-Q   001-40591   10.5   11/14/2024    
    10.24   Form of Secured Promissory Note by and between the Company and the Holder party thereof   10-Q   001-40591   10.2   08/14/2024    
    10.25   Second Amendment to Amended and Restated Senior Secured Note Purchase Agreement and Related Agreements, dated May 1, 2025, between Company and Holder   10-Q   001-40591   10.12   08/18/2025    
    10.26   Equity Purchase Agreement, dated February 20, 2025, between the Company and Square Gate Master Fund - Series 4.   8-K   001-40591   10.1   2/21/2025    
    10.27   Registration Rights Agreement, dated February 20, 2025, between the Company and Square Gate Master Fund - Series 4   8-K   001-40591   10.2   2/21/2025    
    10.28   First Amendment to the Equity Purchase Agreement, dated August 14, 2025, between the Company and Square Gate Master Fund - Series 4.   8-K   001-40591   10.1   08/15/2025    

     

    II-2
     

     

           

    Incorporated by reference

     

    Filed or

    furnished

    herewith

    Exhibit No.   Exhibit title   Form   File No.   Exhibit No.   Filing date  
    10.29   Amended and Restated Amended and Restated License, Research and Co-Development Agreement, dated November 17, 2025, between the Company and Beijing Trimmune Biotech Co., Ltd.   S-1   333-293396   10.40   02/11/2026    
    10.30†#   Amendment 1 to Amended and Restated License, Research and Co-Development Agreement, dated January 27, 2026, between the Company and Beijing Trimmune Biotech Co., Ltd.   S-1   333-293396   10.43   02/11/2026    
    10.31†#   Shareholder Purchase Agreement, dated October 10, 2025, between co-founders of Beijing Trimmune Biotech Co., Ltd., including the Company   S-1   333-293396   10.44   02/11/2026    
    10.32   Exclusive License Agreement 12-Month Suspension, dated May 29, 2025, between the Company and Wugen, Inc.   10-Q   001-40591   10.17   08/18/2025    
    10.33   Settlement Agreement and Release, dated July 13, 2024, by and between the Company and Altor BioScience, LLC, NantCell, Inc., and ImmunityBio, Inc.   10-Q   001-40591   10.6   11/14/2024    
    10.34   Placement Agency Agreement, dated February 17, 2026, between the Company and Maxim Group LLC   8-K   001-40591   10.1   02/19/2026    
    10.35   Form of Securities Purchase Agreement   8-K   001-40591   10.1   5/21/2026    
    10.36   Form of Registration Rights Agreement by and between the Company and the Investors   8-K   001-40591   10.2   5/21/2026    
    10.37   Form of Placement Agency Agreement, by and between the Company and E.F. Hutton & Co. LLC   8-K   001-40591   10.3   5/21/2026    
    10.38*   Form of Lock-Up Agreement                  
    23.1*   Consent of Independent Registered Public Accounting Firm                  
    23.2   Opinion of Clark Hill PLC (included in Exhibit 5.1)                   X
    101.INS   Inline XBRL Instance Document                   X
    101.SCH   Inline XBRL Taxonomy Extension Schema Document                   X
    101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document                   X
    101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document                   X
    101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document                   X
    101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document                   X
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)                   X
    107*   Filing Fee Table                    

     

    + Indicates a management contract or compensatory plan or arrangement.

     

    †† Certain information in this document has been excluded pursuant to Item 601(b)(10) of Regulation S-K. Such excluded information is not material and is the type of information the Registrant treats as private and confidential. The Registrant agrees to furnish supplementally such information to the SEC upon request.

     

    # Certain information in this document has been excluded pursuant to Item 601(a)(5) or (a)(6) of Regulation S-K. The Registrant agrees to furnish supplementally such information to the SEC upon request.

     

    * Previously filed.

     

    II-3
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement on Form S-1 to be signed on its behalf by the undersigned, in the city of Miramar, State of Florida, on June 18, 2026.

     

      HCW BIOLOGICS INC.
         
      By: /s/ Hing C. Wong
      Name:  Hing C. Wong
      Title: Founder & Chief Executive Officer

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Signature   Title   Date
         

    *

    Scott T. Garrett

      Chairman of the Board of Directors   June 18, 2026
         

    *

    Rebecca Byam

      Chief Financial Officer   June 18, 2026
         

    *

    Hing C. Wong

      Chief Executive Officer   June 18, 2026
         

    *

    Rick S. Greene

      Director   June 18, 2026
         

    *

    Lisa M. Giles

      Director   June 18, 2026

     

    By:  /s/ Hing C. Wong  
      Hing C. Wong, Attorney-in-Fact  

     

    II-4

     

    Get the next $HCWB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HCWB

    DatePrice TargetRatingAnalyst
    11/19/2021$10.00Buy
    EF Hutton
    More analyst ratings

    $HCWB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

    Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells Readout for dose-escalating clinical study for first two dose cohorts All participants in second dose cohort at the dose level of 3 micrograms/kg body weight showed positive clinical response after single dose administration Well tolerated, with no dose-limiting toxicities or significant known IL-2-treatment-related adverse effects, including no reported incidence of capillary leak, cytokine release syndrome, or increase in blood eosinophil counts HCW Biologics projects to establish the Recommended Phase 2 Dose by year end 2026 MIRAMAR, Fla., June 16, 2026 (GLOBE NEWSW

    6/16/26 7:00:00 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

    Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, with the potential to support curative outcomes Company plans to commercialize the reagents through corporate partners focused on CAR-T and NK-cell therapies, including developers and manufacturers MIRAMAR, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing first-in-class fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia, today announced t

    5/27/26 7:45:00 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement

    NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the sole placement agent in connection with a $4.0 million private placement for HCW Biologics Inc. ("HCW Biologics" or the "Company") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics designed to treat diseases driven by chronic inflammation, including autoimmune disorders, cancer, and senescence-associated conditions. Joseph T. Rallo, Chief Executive Officer of E.F. Hutton & Co., commented, "We are pleased to have partnered with HCW Biolo

    5/22/26 4:02:37 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Wong Hing C bought $160,000 worth of shares (113,879 units at $1.41), increasing direct ownership by 23% to 615,790 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:26:32 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Garrett Scott T bought $250,000 worth of shares (177,936 units at $1.41) (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:25:09 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Byam Rebecca bought $20,000 worth of shares (14,235 units at $1.41), increasing direct ownership by 33% to 57,245 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:23:30 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    SEC Filings

    View All

    SEC Form EFFECT filed by HCW Biologics Inc.

    EFFECT - HCW Biologics Inc. (0001828673) (Filer)

    6/22/26 12:15:12 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-1/A filed by HCW Biologics Inc.

    S-1/A - HCW Biologics Inc. (0001828673) (Filer)

    6/18/26 1:05:14 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HCW Biologics Inc. (0001828673) (Filer)

    6/16/26 7:15:40 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    EF Hutton initiated coverage on HCW Biologics with a new price target

    EF Hutton initiated coverage of HCW Biologics with a rating of Buy and set a new price target of $10.00

    11/19/21 8:39:08 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Wong Hing C bought $160,000 worth of shares (113,879 units at $1.41), increasing direct ownership by 23% to 615,790 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:26:32 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Garrett Scott T bought $250,000 worth of shares (177,936 units at $1.41) (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:25:09 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Byam Rebecca bought $20,000 worth of shares (14,235 units at $1.41), increasing direct ownership by 33% to 57,245 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:23:30 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Leadership Updates

    Live Leadership Updates

    View All

    HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

    MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.  Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "These are exciting times at HCW Biologics. We achieved two major clinical milestones, with the completion of the Phase 1 clinical study to evaluate HCW9218 in solid tumors and the Phase 1b stu

    4/1/24 4:10:32 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by HCW Biologics Inc.

    SC 13D/A - HCW Biologics Inc. (0001828673) (Subject)

    11/22/24 4:53:35 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Financials

    Live finance-specific insights

    View All

    HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

    MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune disease, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three months ended March 31, 2026. The Company remains on track to provide preliminary clinical data readout from the first two dose levels of the Phase 1 clinical study evaluating HCW9302 in alopecia areata in the first half of 2026. There are two clinical sites actively enrolling patients, and enrollment has been on schedule.

    5/14/26 4:25:00 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results

    MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, today reported financial results and recent business highlights for its three months ended December 31, 2025. On November 17, 2025, the Company initiated its first-in-human clinical trial to evaluate HCW9302, the lead product candidate for the Company's program to develop treatments for autoimmune disorders and proinflammatory diseases, in patients with areata alopecia. HCW9302 is a subcutaneously injectable, first-i

    3/31/26 5:05:40 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

    MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2025.  On May 15, 2025, the Company closed an equity offering with gross proceeds of $5.0 million with a single institutional investor. Dr. Hing Wong, Founder and CEO, stated, "We are pleased to have completed a successful $5.0 million equity offering in a challenging market with

    8/18/25 2:44:03 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care